OmniAb (OABI)

• Market cap: $200M
• 1 day: -11.89%
• 5 days: -18.50%
• 1 month: -22.38%
• 3 months: 22.56%
• 6 months: -54.60%
• Year to date: -53.43%
• 1 year: -62.79%
• 5 years: -83.30%
• 10 years: -83.30%
• Sector: Healthcare
• Industry: Biotechnology

About: OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Employees: 114

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]

80% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 30

7% less funds holding

Funds holding: 151 [Q1] → 141 (-10) [Q2]

7.03% less ownership

Funds ownership: 51.88% [Q1] → 44.85% (-7.03%) [Q2]

22% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 32

37% less capital invested

Capital invested by funds: $152M [Q1] → $95.3M (-$56.7M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 84% upside
• Avg. target: $3 84% upside
• High target: $3 84% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

RBC Capital Conor McNamara

84% upside $3

Outperform Maintained

7 Aug 2025